sess a certain antigen and does not react with cells known not to possess this antigen, one may presume that the antibody is directed against that antigen. This principle of antibody identification is basically unchanged since it was first utilized when Landsteiner discovered the ABO system.' What is less clear, however, is exactly how many antigenpositive and antigen-negative cells should be tested before a definitive antibody identification can be made.
One of us (GG) was asked to comment on the proposed new British Guidelines for Pretransfusion Compatibility Procedures at a public meeting in the United Kingdom, where these guidelines were first presented. One British guideline (6.6.2) states, "The specificity of the antibody should ... be assigned [only] when it is reactive with at least two examples of reagent red cells carrying the antigen and non-reactive with at least two examples of reagent red cells lacking the antigen."2 This proposed guideline was noted (by GG) to contrast with United States guidelines ( e g , the technical manuals of the American Association of Blood Banks3 IAABB] and the American Red Cross4). On the basis of the number of positive reactions against antigen-positive cells and negative reactions against antigen-negative cells, US blood bankers are advised to utilize a poorly understood number called a p value. The p value can be calculated or obtained from tables published in the technical manual^.^*^ According to the AABB Technical Manual, the identity of the antibody can TRANSFUSION 1997;37:816-822.
be definitively identified only if the p value is 0.05 or lew3j5 To obtain a pvalue of 0.05 or less, one needs to test more cells than proposed by the British guidelines. The unknown serum must react with at least three examples of RBCs carrying the antigen and must not react with at least three examples lacking the antigen. This statement is based on calculation of a p value using Fisher's exact test. The American Red Cross Reference Laboratory Methodsand Procedures Manual has an even more conservative approach requiring "antibody identification at a significance level of 0.01 (1%) or l e s~. "~( p~~-~]
The American Red Cross National Reference Laboratory even designed a computer prograd that "calculates p levels, analyzes data entered, and provides the operator with recommendations for further testing in instances where p exceeds acceptable l e~e l s . "~( P~~-"
During an American Red Cross inspection of random reference laboratory reports, the laboratory of one of us (GG) was "chastised" for not achieving a suitable p value when identifjmg an anti-Lea! The validity of the US guidelines was challenged at the British meeting, by one of the authors of the British guidelines (also an author of this article, GP). The arguments put forward by GP appeared reasonable to GG and led him to seek statistical advice from another author of this article (MK); the latter two scientists agreed that the British challenger's arguments seemed logical. Subsequent to the British meeting, the most recent edition of the AABB Technical Manual5 was published. This edition notes that there is an alternative way of calculating the p value, developed by Harris and H~c h m a n ,~ which derives a p value of less than or equal to 0.05 when the unknown serum reacts with only 2 RBC samples having the antigen and does not react with 3 RBC samples lacking the antigen. However, this more liberal guideline is still stricter than the British guideline. This article will delineate the reasons that we believe the indiscriminate use of the p value to calculate the number of RBC samples to test is incorrect. The problems with using a p value in this context can be classified into problems that have to do with the basic nature of a p value, problems that may lead to a false-positive antibody identification, and problems that may lead to a false-negative antibody identification (Table 11. 
CONCEPTUAL PROBLEMS WITH USING A p VALUE FOR ANTIBODY IDENTIFICATION
Misuse of a p value in diagnostic testing To our knowledge, antibody identification is the only area in laboratory testing in which the performance of an identification procedure is evaluated by using a p value. Essentially every other test is characterized by its sensitivity (proportion of patients with disease who have a positive test), specificity (proportion of patients without disease who have a negative test), predictive value of a positive test (proportion of patients with a positive test who have disease), predictive value of a negative test (proportion of patients with a negative test who do not have disease), and efficiency (proportion of patients correctly classified by the test results) .8,9
For purposes of this article, the false-positive rate of a test will be defined as the proportion of patients without disease who have a positive test, and it is therefore equal to 1 -specificity.
The technical manuals of the AABB3s5 and American Red Cross4 state that a p value of 0.05 for an anti-D (obtained by testing 3 D+ samples and finding them to react while 3 D-samples are nonreactive) means that an identical set of reactions due to an antibody other than anti-D could be obtained by chance once in 20 similar studies. Thus, these manuals conclude that there is 95-percent probability that the reactions are indeed due to anti-D. Others10-12 make a similar misinterpretation of the p value. What is forgotten is that the p value is a conditional probability. It is the probability of observing the reactions assuming that the antibody either is notanti-D or is at least not related to anti-D.
In an unknown serum with only one antibody, there are two possibilities. Either the serum contains anti-D or it contains an antibody other than anti-D. One can consider the identification of anti-D as a positive result and the identification of another antibody as a negative result. Using a p value of 0.05 in antibody identification means that if one has a non-Rh antibody, it will be incorrectly identified as anti-D 5 percent of the time. (If one has an Rh system antibody other than anti-D, this interpretation is incorrect, because antigens in the same blood group system do not occur in a statistically independent fashion as discussed below.) Thus, the specificity is 95 percent and the false-positive rate is 5 percent. Browner and Newman13 previously noted that the p value can be deemed analogous to the false-positive rate (1 -specificity).
The incorrect interpretation of the p value noted above3~5~10-12 is actually that of the positive predictive value (PV) of the antibody identification, rather than the falsepositive rate. These quantities have been related by using Bayes' theorem8 which states:
For simplicity, if the antibody is sufficiently strong, the antibody will react with all antigen-positive cells and will not react with any antigen-negative cells. Under these circumstances, if there are no errors in the interpretation of results, one can assume that the antibody panel has a sensitivity of 1. The above equation can then be written using statistical terms by substituting p for (1 -specificity).
The prevalence of an antibody in this context is best thought of as the a priori probability that the suspected antibody ( e g , anti-D) is present.
It should be noted that the relationship between the p value and the PV is complex and dependent on the a priori probability of the antibody in question. The PV decreases as the a priori probability decreases. Blood bankers should be aware that using the same p value (e.g., 0.05) on sera with different a priori probabilities may result in markedly different PVs. Table 2 shows the effect of changing the p value from 0.05 to 0.167 (the p value, calculated by us, that would be obtained by using the British guidelines) on the PV for various a priori probabilities when the sensitivity is 1. As can be seen, when the a priori probability is fairly high, the effect of the p value on the PV is quite small. Shulman et al.,I4 in fact, studied an unusually well defined patient population in which the a priori probability of finding anti-D was over 0.90. Although they did not use the PV model, Shulman et al.14 seemed to have intuitively recognized that Fisher's p value of 0.05 was too conservative for their patient population, and they recommended ignoring the results of Fisher's exact test and using only 2 samples of D+ RBCs and 3 samples of D-RBCs (p = 0.10 by Fisher's exact test). Table 2 indicates that, in this population, using either the recommendations of Shulman et al.I4 or the British guidelines would also yield acceptable results.
FeinsteinI5 has noted that, with the exception of studies involving a well-defined population such as that used by Shulman et al.,I4 one severe and often unappreciated limitation of using PVs is that the prevalence or a priori prob- ability is, in general, unknown. The overall frequencies of various antibodies occurring in one's laboratory should not be equated with the a priori probability that an antibody exists in an individual case. Specifically, the a priori probability depends on any existing records of previously identified antibodies, the patient's phenotype, administration of certain drugs ( e g , Rh immune globulin), and the temperature at which the antibody reacts best, as well as whether it is detected with anti-lgG or anti-complement, whether dosage is noted, whether some specificities can be eliminated by noting the failure of a reaction in one or more positive cells, or whether there are other characteristics of the antibody that an experienced blood banker may note. We are not advocating replacing the widespread use of p values with the use of PVs, because of the inability to precisely quantitate the a priori probability of a specific antibody as well as several other problems with calculating p values or their analogues (1 -specificity) (see below). Nonetheless, the general principle of interpreting an antibody panel by its PV (even if based on one's best guess or intuition about the a priori probability) should not be ignored.
Performing a statistical test on nonstatistical data
To the best of our knowledge, the use of Fisher's exact test to identify antibodies was first reported in 1950 by Race and Sanger.16 It should be remembered, however, that, at the time, only a few blood groups had been identified, and many serologic reactions remained a mystery. The work of Race and Sanger was done at an exciting time in blood group serology, when they must have been regularly examining blood group antibodies never before described. In those circumstances, performing a statistical test is valid. A "new" antibody reacting with 3 E+ samples and not reacting with 3 Esamples might indeed not be anti-E. The average situation in a laboratory in 1997 is surely different. Antibody panels routinely have cells that are typed for antigens corresponding to the most commonly occurring antibodies. Unlike in the 1950s, today one can exclude the presence of all of these clinically significant antibodies.
Since an antibody's specificity is almost always to an antigen listed on the panel, in most cases, the reaction pattern should have no random component, and therefore statistical analysis is superfluous.
Overemphasis on a p value of 0.05
Salsburg17 noted that the use of 0.05 as a value of p that determines "significance" is totally arbitrary, and, in fact, p values of 0.04, 0.05, or 0.06 are virtually the same. All indicate that the null hypothesis is probably incorrect.
The use of a p value of less than 0.05 to indicate statistical significance is so ingrained that many published articles by blood bankers actually fail to state what value of p is considered significant.lB Nonetheless, there are circumstances when one might use a higher or lower p value. In antibody identification, a higher p value results in lower specificity of the identification. Suppose one identifies an anti-c with a p value (by Fisher's exact test) of only 0.17 (2 examples of positive RBCs react and 2 examples of negative RBCs do not). Regardless of the p value, one would be obligated to make sure that all other common, clinicallysignificant antibodies have been excluded as possibilities. If all of these antibodies are excluded, what is the consequence of incorrectly identifying the antibody as anti-c? With extremely rare exceptions, the reactions observed would be from an antibody not usually associated with serious clinical sequelae. Incorrectly concluding that the antibody is anti-c may result in a future transfusion with c-negative blood. Other than the expense and inconvenience, it is extremelyunlikely that there will be harm to the patient.Thus, small differences in the p value (1 -specificity), which, as we have seen, may have an even smaller effect on the rate of false identification of antibodies (1 -PV), are not usually important.
Misundeistanding the null hypothesis in Fisher's exact test
The null hypothesis in Fisher's exact test is often misstated. Judd states erroneously, ' R p value of 0.05 for an anti-D...means that an identical set of reactions due to an antibody other than D could be obtained by chance once in 20 similar studies.""(P2") Menitove,Ig however, correctly noted that Fisher's exact test is actually testing for statistical independence between the presence of a reaction and the presence of a specific antigen. Fisher's exact test does not test whether or not a specific antibody could, by chance alone, result in the reactions that were observed. It is certainly true that, if there is no statistical association between an antigen and the observed serologic pattern of an antibody, then the antibody is not directed against that antigen. The converse, however, is not true.
For example, imagine that one tests 40 samples of RBCs with an unknown antibody and obtains the following contingency Using a one-tailed Fisher's exact test, the p value is 0.048. If one were incorrectly using the null hypothesis stated by Judd" and the manuals of the AABB3 and American Red Cross,4 one would conclude that the possibility of an antibody other than a n t i 4 is excluded, and thus one would be forced to identify this antibody as anti-S. It is hoped, however, that, in practice, workers would realize that the number of discrepant reactions virtually excludes a n t i 4 from serious consideration. The correct interpretation of this p value is that there is some evidence of an association between the antibody and S. Most likely, the antibody is reacting to another antigen in the MNS system.
PROBLEMS THAT MAY LEAD TO A FALSE-POSITIVE IDENTIFICATION Disregard for confounding variables
A confounding variable is a variable that is associated with both the variable being studied and the outcome being Disregard for confounding variables has been suggested to account for the misinterpretation of data concerning the risks of immunomodulation after blood transfusion2' and the misinterpretation of data concerning the relative safety of directed and allogeneic blood donors.22 This disregard of confounding variables may also affect antibody identification. In the context of antibody identification, the outcome is the presence or absence of a reaction. The variable being studied is an antigen corresponding to the suspected antibody. A confounding variable would be any other antigen associated with the antigen being studied. This association may be completely fortuitous. Any significant association between the presence of a reaction and the suspected antigen may in fact be due to the confounding antigen.Thus, before identifylng any antibody, one must, by appropriate testing, eliminate from consideration all other clinically significant antibodies. This counsel is not usually given with statistical terms such as confounding variables, but it is nevertheless familiar to all blood bankers. Besides excluding confounding antigens, elimination of all other clinically significant antibodies has the effect of increasing the a priori probability of the presence of the suspected antibody (and thus increasing the PV).
Failure to eliminate all possible clinically significant antibodies may result in a false antibody identification. For example, a high proportion of misidentifications of anti-Jkb was noted in a 1995 UK survey.u This was attributed to the use of an antibody panel whose arrangement of Jk(a-b+) matched that of K+. Smith et al.24 also noted the tendency for technologists on occasion to identify antibodies on the basis of a consistent pattern of reaction, without first ruling out other possible antibodies. It should be recognized, however, that the elimination of all possible remaining antibodies is sometimes not straightforward. For example, if, in a panel, all S+ cells are also M+N-, and vice versa, then a"dosing" anti-M may appear like an anti-S. A p value calculated for the a n t i 4 may be significant even though the antibody is anti-M. Exercises such as this emphasize the importance of the technologist's experience in this complex field and the superiority of such experience over calculations such as p values.
Discrepant results
When one obtains a discrepant reaction pattern (e.g., when an antibody that appears to be anti-e reacts with one or more samples of e-RBCs or fails to react with a sample of e+ RBCs), one can still mathematically calculate a p value. The interpretation of this p value becomes problematic, however, and is related to the issue of false-positive and falsenegative reactions noted previously. The AABB Technical M~n u a P~~ gives an example of positive reactions with 8 samples of e+ RBCs and negative reactions with 1 sample of e+ RBCs and 3 samples of e-RBCs. The presence of a negative reaction in even 1 sample of e-positive RBC means (if one can be sure that there are no errors or false-negative reactions) that the antibody is not anti-e. The Technical Manual, however, using Fisher's exact test, states that p = 0.018, which is considered diagnostic of anti-e.
In practice, one should make a judgment as to whether the negative reaction with the e+ cell was a false-negative reaction. This judgment might be based on obtaining more information, such as the reaction strengths observed, the zygosity of the panel cells, any decrease in antigens in the panel cells that is due to improper storage or some other problem, the patient's phenotype, the temperature of reactions, or perhaps the use of enzymes. Blindly basing the identification of anti-e on a p value below 0.05 without finding a reasonable explanation for the negative reaction or examining some of the above-mentioned evidence would not seem to be optimal blood-banking practice. Smith et aLZ4 recognized that accurate antibody identification is dependent upon considering all of the evidence (not just the number of positive and negative reactions or resultant p values) and making sure all such evidence converges to the same conclusion.
Inappropriate post hoc statistical testing
For a statistical test to be valid, one must specify exactlywhat will be analyzed before the data are collected. Performing a statistical test that was not planned before data collection is called data snooping or dredgingE Any p value obtained is artificially low.
When antibody panels are analyzed, one usually does not state in advance the antibody for which a p value will be calculated. Instead, one first examines an antibody panel that may contain cells typed for dozens of antigens. One calculates a p value only for those antibodies that one suspects are present after inspection of the panel. This type of post hoc statistical testing leads to a falsely low p value. This problem was recognized by Race and Sanger many years ago.z6 They solved it by recommending the use of a smaller p value to indicate significance. They stated, "Our general rule is not to get too excited until the probability is less than 1 in 100, but at about that level, to begin the investigation again, on fresh material, with the one comparison in mind."26(p48z-3J They recommended using a p value of 0.05 only on the second investigation. Their advice has been noted only rarely by subsequent blood bankersz7 and appears to have been largely ignored.The astute reader should also note that Race and Sangerz6 do not rigidly refer to an exact p value that is interpreted as defining significance, but instead write in more vague terms.
Sequential statistical testing
A problem related to post hoc testing is sequential testing, which refers to an examination of a set of data. If a p value is only approaching significance, additional data are examined and repeat statistical testing is performed. An example of this is noted in the AABB Technical M~n u a l ,~~~ where, after noting that an initial p value is only 0.067, more samples are tested and a new p value (0.018) is calculated as if the first p value was never obtained.
Unfortunately, this analysis is incorrect. If one sets a p value of 0.05 as the level of significance required, the first time one performs the statistical test, there is a 0.05 probability of falsely concluding significance when none exists. If one then studies more RBC samples and performs another statistical test on the data, there is a second chance (with its associated probability) of falsely concluding significance when none exists. The total chance of falsely concluding significance is therefore greater than either of the two probabilities and thus is greater than 0.05. If more than one test is to be performed sequentially during the antibody identification, each test must be performed at a lower p value.z8
PROBLEMS THAT MAY LEAD TO A
Disregard for false-positive and false-negative reactions Calculation of p values assumes that all reactions are correctly observed. The only random component considered is the presence or absence of an unknown antigen. The statistical methods used in the calculation of the p value ignore the probability of error due to technical mistakes or weak or equivocal reactions. It is difficult to quantify the probability of this error, and such clarification would in any case depend upon the level of quality assurance, training, and so on.
FALSE-NEGATIVE IDENTIFICATION Disregard for the conditional nature of Fisher's exact test
Another, more serious problem with Fisher's exact test is that the value of p is conditioned upon the total number of positive and negative reactions being that which is observed. It is only the distribution of positive reactions between the antigen-positive and antigen-negative RBCs that can vary. If a serum reacts against 3 samples of D+ RBCs and does not react against 3 samples of D-RBCs, Fisher's exact test calculates the probability that a non-Rh system antibody would react this way assuming that it reacted against exactly 3 of 6 samples. For antibodies against antigens with either a very high or very low frequency, it is unlikely that one will observe reactions in exactly 3 of 6 samples of RBCs, and thus the conditional nature of Fisher's p value becomes problematic.
In reality, however, if an antigen has a population frequency off, the probability of finding reactions in D+ cells and no reactions in D-cells when the antibody is not related to anti-D is fa(l-f)b, where a is the number of positive reactions and b is the number of negative reactions7 This formula assumes that cells are selected randomly with respect to the antigen in question, and thus it applies only to antigens not specifically tested for by the manufacturer of a panel. For either very rare or very common antigens (population frequency <0.05 or >0.95), the probability is ~0.00011 These large differences are due to the fact that an antibody directed against an antigen with a frequency of ~0 . 0 5 or >0.95 will likely not react against 3 of6 samples. Fisher's exact test, however, calculates the p value assuming that theserum reacts with 3 of 6 examples of cells.
Alternative method of calculating p values
The conditional nature of Fisher's exact test has been well described by Harris and H~c h m a n ,~ who propose an alternative method of calculating a p value on the basis of antigen frequencies. That is, they would ask: what is the likelihood that the cells with positive reactions are also positive for an unknown antigen Q and that cells with negative reactions are also negative for antigen Q?This is the approach taken in the preceding paragraph. The problem with the approach of Harris and Hochman is that antigen Q is unknown, and therefore its phenotypic frequency is unknown. To circumvent this problem, they arbitrarily used the frequency that maximized the p value. In the case with 3 reacting samples and 3 nonreacting samples, they use a population frequency of 0.5 and obtain a p value of 0.016. For the extremely rare or common antigen (frequency, <0.05 or >0.95), the p value of Harris and Hochman (like that of Fisher) is substantially higher than that calculated in the previous section. If one examines antigens that have a frequency >0.05 or c0.95 and are not necessarily included in the antigen profile of every panel cell, one is left with antigens such asYtb, Doa, Dob, Cob, McCa,Yka, Bg", Sda, and LW.26 For instance, Ytb and Cob have an antigen frequency of 0.08 and 0.087, respectively. The probability that these latter two would react with 3 examples of D+ RBCs and not react with 3 examples of D-RBCs is still only 0.0004 and 0.0005, respectively. Doa has the frequency (0.66) closest to 0.5 with an associated p value of 0,011, but the p value changes quite rapidly as the antigen frequency moves farther away from 0.5.
There is another problem with Harris and Hochman's p values. If a reaction pattern appears to be an anti-D, the null hypothesis is that there is some unknown antibody, anti-Q, which is re-ally present. If one calculates a p value of ~0.05, one can reject the null hypothesis. This does not mean that the antibody is anti-D. There are potentially many other antibodies (e.g., X,Y, Z) that are possible. The problem, then, is that the alternative hypothesis (i.e., the hypothesis taken when the p value is c0.05) does not unambiguously define an antibody specificity.
ESTIMATE OF THE HISTORICAL PERFORMANCE OF p VALUES IN ANTIBODY IDENTIFICATION
Looking back to the time when most antigens were not known and using the now-known antigen frequencies (f), we can calculate what the p values should have been, on the basis of the formula p = fa(l-fIb. Table 3 shows the probability of observing a positive reaction when a suspected antigen (i.e., D) is present and a negative reaction when the suspected antigen (D) is not present for various non-Rh system antibodies. For example, suppose one observed a reaction in 2 samples of D+ RBCs and no reaction in 2 samples of DRBCs. The probability that an anti-Jk" would cause this pattern is obtained in the second column and is 0.03. As one can see, p values differ widely for different antibodies. It can also be noted that the use of two examples of positive reactions and two examples of negative reactions, as proposed by the British guidelines, is associated with a p value c0.05 for all antibodies except anti-S, which is only 0.06. More important, it should be noted that, as both Fisher's and Harris and Hochman's p values are only fairly crude approximations, it does not appear to make sense to rigidly adhere to a value c0.05.
INSIGNIFICANCE OF STATISTICAL TESTING IN ERROR RATES
A recent British survey of error rates in antibody identificationU shed some light on the accuracy of that process. The error rate for various samples of anti-D varied from 0 to 7.1 percent. If a false identification was made primarily because of the fortuitous occurrence of some antigen on D+ cells and not on D-cells, the error rates should be similar from exercise to exercise. The variation observed (from 0 to 7.1%) suggests that technical problems or problems with false-negative reactions were the more commonly a source of error.
Smith et aLZ4 studied actual patient samples submitted for antibody identification and found 41 errors in 1057 cases. A variety of technical and clerical errors were noted. Although the authors admit that some errors may not have been identified, they did not find any cases of misidentification of antibodies due to statistical chance.
SUMMARY
P values as calculated for antibody identification have many sources of error and are only a crude estimate of the correct p value. In addition, the p value estimates only 1 -specificity and ignores the sensitivity and PV of the antibody panel.
Antibody identification should rely on the elimination of all other common, clinically significant antibodies, as well as on the characteristics of the antibody (e.g., temperature of reactions, reactions with anti-IgG or anti-complement, and dosage) and any other available information. Instead of rigid adherence to requiring a p value c0.05, the accuracy of antibody identification can better be improved through the implementation of rigorous quality assurance programs and meticulous attention to technique. The number of reactions required for identifymg an antibody should not be based on the misuse and misinterpretation of p values. Currently, there is no scientific basis for any requirements as to the number of reactions to observe in antibody identification. The recommendations in several t e~t s~-~-l~ appear to be based on flawed statistics. There is no evidence that recommendations such as the British guidelines that require fewer cells to be tested will perform less well than the recommendations of the American guidelines.
